Financial Report
PolyPeptide Half-year Report 2023
1 January - 30 June (unaudited)
|
kEUR |
Note |
H1 2023 |
H1 2022 |
|
|
|
|
|
|
Revenue |
4 |
131,834 |
133,656 |
|
Other operating income |
|
1,544 |
954 |
|
Total income |
|
133,378 |
134,610 |
|
|
|
|
|
|
Cost of sales |
5 |
-144,006 |
-96,776 |
|
Gross profit / (loss) |
|
-10,628 |
37,834 |
|
|
|
|
|
|
Marketing and sales expenses |
|
-1,993 |
-2,589 |
|
Research expenses |
|
-746 |
-656 |
|
General and administrative expenses |
5 |
-21,097 |
-19,107 |
|
Total operating expenses |
|
-23,836 |
-22,352 |
|
|
|
|
|
|
Operating result (EBIT) |
|
-34,464 |
15,482 |
|
|
|
|
|
|
Financial income |
|
21 |
4 |
|
Financial expenses |
|
-4,784 |
-2,645 |
|
Total financial result |
|
-4,763 |
-2,641 |
|
|
|
|
|
|
Result before income taxes |
|
-39,227 |
12,841 |
|
|
|
|
|
|
Income tax |
|
4,961 |
-2,594 |
|
Result for the period |
|
-34,266 |
10,247 |
|
|
|
|
|
|
Attributable to shareholders of PolyPeptide Group AG |
|
-34,266 |
10,247 |
|
|
|
|
|
|
Earnings per share in EUR, basic |
|
-1.04 |
0.31 |
|
Earnings per share in EUR, diluted |
|
-1.04 |
0.31 |